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Hodgkinson et al TMEM43 p.S358L ARVC: Long-Term Outcome After ICD PP). 13, 14 The most recent consensus statement on treatment for ARVC defines the ICD as being indicated in high-risk patients after sustained VT/VF. 15 We previously reported outcomes after ICD in 11 families with ARVC because of TMEM43 p. S358L and showed a statistically significant survival benefit for males, regardless of presentation. 16 The efficacy of ICD treatment is important because the ICD is not risk-free. [17] [18] [19] Inappropriate discharges, lead fracture and displacement, infection, and psychological sequalea 20 are adverse outcomes that must be considered when offering ICD therapy to presymptomatic individuals. A randomized control trial, however, would be unethical based on our earlier results 16 and the overwhelming evidence for the prevention of SCD after ICD in individuals with left ventricular systolic dysfunction. 21 Several genes have been implicated in the pathogenesis of ARVC 22 with mutations that present variable natural histories because of pathogenicity, penetrance, and variable expressivity. Determining the effectiveness of therapy for ARVC is thus based on heterogeneous cohorts, which additionally reflect a biased ascertainment of individuals who (1) survive to present with evident clinical disease and (2) do not present because they are minimally affected. Mutation-specific information is thus helpful when deciding whether to aggressively pursue presymptomatic treatment.
We report long-term clinical outcome data following ICD therapy (median follow-up 8.5 years) for TMEM43 p. S358L mutation carriers. The deep family genealogies provided many untreated mutation carriers (including obligate carriers) as a control group matched for age, disease status, sex, and family to assess survival. Cases were stratified by indication for ICD: PP in those with the p.S358L mutation without a documented cardiac event or SP after sustained VT/VF (subsequently shown to have the TMEM43 p.S358L mutation). Study questions included (1) whether the survival benefit in males previously described 16 persisted with longer follow-up (given the potential for heart failure leading to cardiac transplantation), (2) whether benefit was observed for both PP and SP ICD treatment in both males and females, (3) whether a shock for VT/VF was equivalent to an aborted death, and (4) whether we could identify independent clinical test predictors of appropriate ICD discharge measured before implantation.
Methods

Study Population
Consent for retrospective and current chart review and for genetic analysis was obtained from each individual (or surrogate) in compliance with our institutional review committee and regional ethics board (study no. 00.176). Of 826 families referred to the NL provincial cardiac/genetics program because of a family history of cardiomyopathy or SCD, 24 had autosomal dominant ARVC caused by a p.S358L mutation in TMEM43 7 and met TFC in at least one affected person in each family. 4, 5 Extensive (≤10 generations) family histories were obtained from which 862 individuals who were born at an a priori 50% pedigree risk (which includes affected individuals, unaffected individuals, and those remaining at 50% risk) were identified. The use of data from across generations in families with a clear autosomal dominant pattern allowed us to make diagnoses when the first clinical event was SCD and the requisite (tertiary) clinical testing was not undertaken. SCD was defined if (1) the death was unexpected, (2) it was witnessed (≤1 hour) or not witnessed (≤24 hours), 23 and (3) the death was defined as cardiac (excluding CAD) or likely arrhythmia on autopsy. All available clinical records and autopsy reports were obtained. Affected individuals (n=393) were defined based on any or all of the following: (1) obligate carrier status by pedigree analysis (an individual with both an affected child and a parent), (2) the presence of the p.S358L TMEM43 mutation and, (3) documented sustained VT/ VF or otherwise unexplained SCD before 50 years of age. 6 Unaffected individuals (n=229) were defined by the absence of the p.S358L mutation. All others (n=240) were considered unknown status (UK; Figure 1 ).
The majority of at-risk family members were managed at the Provincial Cardiac Genetics Clinic 24 which provided cardiac screening, including12-lead ECG, signal averaged ECG, Holter monitor, echocardiography, and magnetic resonance imaging alongside genetic counseling and genetic testing. Subsequent to diagnosis and treatment, individuals were followed-up by an ICD clinic for device monitoring.
Indication for ICD Treatment
ICDs were initially used in these families for SP after documented sustained VT/VF with the earliest ICD provided in 1993. From 1998 onward, all ICD treatment decisions for NL residents were made by one electrophysiologist (Dr Connors), and the majority of ICDs (72%) were provided between 2000 and 2009 following (1) cascade screening of relatives and (2) genetic results obtained initially using a research-generated disease-associated haplotype 24 and later direct mutation analysis. 7 The ICD was recommended immediately in mutation (or haplotype)-positive postpubertal males and following any abnormal cardiac clinical test in females (ventricular ectopy, poor R wave progression [PRWP], prolonged QRS, documented dilatation of the left or right ventricle, or reduced ejection fraction). PRWP is a clinical feature seen in this genetic subtype of ARVC. 6, 25 Eight females (12%) with normal cardiac testing had an ICD based on patient request. To date, 148 individuals have ICDs: 80 males and 68 females (Figure 1 ). Of these, 134 (91%) implantations were in NL, 12 (8%) in mainland Canada, and 2 (1%) in the United States.
Programming and Classification of ICD Discharges
In ICDs for PP, programming for therapy and detection was typically for rates >200 beats per minute. The number of intervals was programmed between 24 and 30 depending on the device manufacturer. Where device technology allowed, ATP was used as the first therapy. In SP ICD individuals, 2 or 3 zones for detection were programmed. SVT discriminators were also used, including morphology analysis.
WHAT IS KNOWN
• Arrhythmogenic right ventricular cardiomyopathy (ARVC) has multiple genetic subtypes and an extremely variable clinical picture.
• Recent literature suggests implantable cardioverter defibrillator (ICD) therapy is indicated in high risk patients.
WHAT THE STUDY ADDS
• For the genetic subtype of ARVC caused by TMEM43, p.S358L, ICD treatment based on genotype alone provides a significant survival advantage, so primary prophylaxis with an ICD is indicated.
• For the genetic subtype of ARVC caused by TMEM43, p.S358L, Task Force Criteria are not necessary in ICD treatment decisions.
• In the absence of a randomised control trial, design strategies which include historic family information and ascertain individuals at varying clinical stages of a progressive disease provide robust treatment efficacy data. TMEM43 p.S358L ARVC: Long-Term Outcome After ICD All ICD stored data were analyzed, and all treatment events were documented: ICD discharges, precipitating heart rate, anti-tachycardia pacing events, and episodes of nonsustained VT. Inappropriate discharges included all non-VT dysrhythmias and discharges related to lead fracture and electromagnetic interference. Time to first appropriate discharge for sustained VT/VF for any rate and for ≥240 beats per minute was assessed.
Study Design
This is a prospective cohort study comparing survival in individuals with and without an ICD (exposed versus unexposed). Cases and controls were stratified by sex and indication for ICD. Before implantation, potential clinical predictors of ICD discharge were obtained from 12-lead ECG, Holter monitor, and echocardiographic test results. Serial retrospective clinical data on all individuals were obtained where available (including clinical events, cardiac and genetic testing), and effort was made to collect data from family members outside NL. Prospective clinical data has been accrued since 1998. Survival after ICD was compared with controls without an ICD using a matching strategy previously described. 16 Briefly, family controls were affected individuals who did not receive an ICD, were of the same sex, were born after 1920, and who survived to the same age-tothe-day (time zero for the analysis) at which the ICD recipient (case) received their device. Where possible, affected controls were from the same family as the ICD recipient (n=101/148: 68%) with the remaining 47 (32%) of controls obtained from the closest geographically available family. Matching individuals from families not genealogically linked seems reasonable because the families share a founder haplotype and are thus genetically related. 7, 9 All ICD complications (unrelated to manufacturer recall) were documented.
Outcomes
The primary outcome was survival from the start of the study (time zero: the point of ICD implant or the exact age in a control individual). Secondary outcomes included time to appropriate ICD discharge at any rate of VT/VF and at VT/VF ≥240 beats per minute. The predictive value of clinical test results on appropriate ICD discharge was assessed using (1) ectopy on Holter monitor (≥1000 premature ventricular complexes [PVCs]), (2) PRWP on 12-lead ECG, and (3) reduced ejection fraction on echocardiography and were analyzed using univariate and multivariate models. These clinical parameters were chosen based on our previous work. 6 
Statistical Analysis
We used version 22 of the IBM SPSS statistics package for statistical analyses (IBM Corporation, Armonk, NY). A P value of <0.05 was considered significant. Survival was calculated according to the Kaplan-Meier product limit method. Relative risk was calculated using Cox's Regression model. All cumulative incidences were calculated from the Kaplan-Meier analysis, and the significance of the differences between the groups was tested by the log rank. Categorical variables were assessed using Chi-square. Follow-up continued until death or last follow up (March 2015). Outcomes were analyzed for males with an ICD for PP and SP and for females with an ICD for PP because only 2 females had an ICD for SP. Table 1 provides demographic data, method of diagnosis, and outcomes of the cases and controls. Of 80 males, 61(76%) received ICDs for PP at a median age of 27.6 years and 19 (24%) for SP at a median age of 39.7 years. Sixty-six (97%) of 68 females received ICDs for PP at a median age of 42.9 years. All PP individuals were defined as affected by mutation status, 88% of whom were born after 1950; in contrast, 44% of PP controls were born after 1950, of whom 33% were defined by mutation status reflecting the matching strategy of using relatives from earlier generations before the availability of the ICD. The age at entering the study was the same in the control group as the ICD group, again reflecting the matching strategy. Thirteen percent of controls were treated with antiarrhythmic drugs, half of whom were given Amiodarone. Of the 80 male controls, 65 had an SCD (74%). Of these, 13 (20%) had data from a Holter or telemetry, all of whom had multiple PVCs but no documented VT. For the 66 female controls, 13 had an SCD (20%). Of the 3 (23%) with clinical data, all had multiple PVCs with no documented VT.
Results
Survival Following ICD
Males who received an ICD for PP were followed for a median of 6.2 years (from 3 months to 14 years) and their control group for a median of 8.6 years (from 1 month to 23.7 years). The Figure 2A ). Males who received ICDs for SP were followed for a median of 13 years (from 6.1 years to 22 years) and their control group for a median of 5 years (from 1 month to 15 years). The 5-year survival rate was 100% compared with 50% in controls (RR 9.7; 95% CI 3.2-29.6; Figure 2B ). There was no difference in survival between the controls based on allocation (PP or SP controls; Figure I in the Data Supplement). The females who received an ICD for PP were followed for a median of 8.5 years (5 months to 16.5 years) and their control group for a median of 11 years (from 4 months to 53 years). The 5-year survival rate in females was 97% compared with 85% in controls (RR 3.6; 95% CI 1.3-9.5; Figure 2C ).
Cardiac Transplant
Eight individuals (7 males and 1 female) received a heart transplant following ICD for heart failure because of cardiomyopathy (6 males and 1 female) and intractable VT (1 male). Two control group individuals received a heart transplant. Time to heart transplant, death, or last follow-up was significantly better in ICD groups compared with control groups (Figure II in the Data Supplement).
Time to First Appropriate ICD Discharge for Sustained VT/VF
Of the 61 males who received an ICD for PP, 59 had outcome data available, 51% of whom had appropriate therapy from their ICD (discharge, pacing, or both). Twenty-four ICD individuals (42%) had at least one appropriate discharge, 21 (88%) for VT/VF (≥240 beats per minute) and 3 (12%) for VT(<240 beats per minute). The 5-year cumulative incidence rate of discharge for the PP males was not significantly different from the 5-year mortality in the PP control group whether for VT at any rate ( Figure IIIA in the Data Supplement) or for VT/VF (≥240 beats per minute; Figure 3A ). Of the 19 SP males, data were available for 14, of which 9 (64%) fired for sustained VT (<240 beats per minute) and 5 (36%) for VT/VF (≥240 beats per minute; Figure 3B ). The cumulative incident rate of discharge for VT for any rate at 5 years was statistically different from the 5-year mortality (RR 5; 95% CI 1.8-13.8) in the SP control group (Figure IIIB in the Data Supplement), whereas the cumulative rate of discharge for VT/VF (≥240 beats per minute) at 5 years was the same as the 5-year mortality in the SP control group ( Figure 3B ). PP males thus present differently than SP males, with 88% of the former with VT/ VF ≥240 beats per minute as their first presentation compared with 36% of SP patients (P≤0.004). Of the 66 females with ICDs for PP, data were available in 60 individuals, 15 (25%) of whom had at least one appropriate discharge, 3 (20%) for VT (<240 beats per minute) and 12 (80%) for VT/VF (≥240 beats per minute). The 5-year cumulative incident rate of discharge for the PP females was not significantly different from the 5-year mortality in the PP control group whether for VT at any rate ( Figure IIIC in the Data Supplement) or for VT/VF (≥240 beats per minute; Figure 3C ).
Clinical Predictors of Appropriate ICD Discharge for VT at ≥240 Beats Per Minute
Because the incident rate of appropriate discharge for VT ≥240 beats per minute was the same in males who received an ICD for PP or SP ( Figure 3A and 3B) , we combined the Table 2 provides the predictive value of symptoms and cardiac test abnormalities at the time of ICD implantation and their association with subsequent ICD discharge for VT/VF at ≥240 beats per minute, stratified by sex. At receipt of the ICD, 31% of males had PRWP, 22% had a reduced ejection fraction (mild-severe), and 57% had ≥1000 PVCs in 24 hours. Although there was a significant association of each test abnormality with subsequent discharge on univariate analysis (Table 2) , in the multivariate model, ≥1000 PVCs was the only significant independent predictor (RR 5.8, 95% CI 1.3-27). Although 51% of females had PRWP, 13% decreased ejection fraction, and 47% ≥1000 PVCs in 24 hours, no clinical predictor was significant in females (Table 2 ). ICD problems, including lead fracture/replacement or device malfunction leading to morbidity and mortality, occurred in 2% of the ICD cohort. Inappropriate discharges occurred in 27% of PP males, 36% of SP males, and 18% of females and were because of sinus tachycardia in 52%, nonsustained VT in 22%, T wave oversensing in 15%, and atrial fibrillation in 8%. In the entire cohort, 19% had repeated appropriate discharges (21 to >50) and 6% had repeated inappropriate discharges (21 to >50). We found no difference in ICD programming for those with and without inappropriate discharges.
Discussion
Our long-term follow-up of the effectiveness of ICD therapy in ARVC families with a p.S358L mutation in TMEM43 clearly shows that males obtain a significant and substantial survival benefit whatever the indication for ICD and that females obtain a significant albeit smaller benefit.
Initial reports of outcomes after ICD in ARVC 14, [26] [27] [28] assessed SP, with more recent reports defining the efficacy of PP. 13, 14, 26, 29 For example, appropriate ICD discharge for VT/ VF occurred in 21% of 14 Dutch PP ARVC patients 26 and 25% of 106 PP ARVC patients from 6 centers in Europe and North America 14 compared with 42% of the males in this study and 25% of females. Caution has been expressed regarding the use of the ICD as a prophylactic measure in families presenting with a history of SCD because of several heritable cardiac conditions. 30 However, all previous studies of the use of ICDs in ARVC were in genetically heterogeneous groups or in groups with an undetermined genetic cause. Recent consensus statements suggest that ICD therapy for ARVC is indicated after sustained VT/VF. 15 The results from our homogeneous cohort, however, indicate clearly that in male TMEM43 p.S358L mutation carriers, ICD treatment should be offered early and before clinical evidence of the presence of disease. The youngest male SCD in this population was 19 years, and we have documented expression of clinical disease in teenagers. The importance of early disease in males is underscored by the significant difference in the rate of the first ICD discharge in the PP versus the SP males, where the former primarily present with malignant VT/VF at rapid rates ≥240 beats per minute compared with the latter where the majority present with VT <240 beats per minute. This significant difference in presentation likely reflects the survival bias in the SP patients where they survive slower episodes of VT. This allows them to present clinically to receive an ICD and highlights that the first presentation is often SCD in the absence of an ICD in young males.
We have also shown that ICDs provide a significant survival benefit in females: an important outcome given the more benign phenotype. The mean age of females receiving an ICD was 43 years, and an early separation of the survival curves is observed ( Figure 2C ). The earliest confirmed deaths in females were sisters aged 37 and 43 years, supporting the use of a PP approach in females at an earlier age than these mutation-confirmed deaths.
Remaining challenges include (1) the need to define with greater precision the timing of ICD implantation in the female population and (2) the question of prophylactic ICD use in prepubertal males exhibiting clinical symptoms. To date, our youngest male ICD recipient was 13 years after documentation of ≥1000 PVCs on 24-hour Holter monitor. We would recommend that the clinical decision in these cases be individualized.
The question has been raised as to whether VT discharges ≥240 beats per minute in ARVC patients with otherwise mild/ normal cardiac function should be considered as aborted death events, given that these episodes might be tolerated and nonsustained. 13, 14, 31 Our results indicate that such discharges in all groups are a surrogate mortality event. We also show that discharges for a sustained rate of VT <240 beats per minute occurred infrequently in those who received an ICD for PP and were not equivalent to an aborted death in SP males. All the abnormal clinical test results assessed in males were predictive of ICD discharge at a VT/VF rate of ≥240 beats per minute, but the only independent and significant predictor was PVCs ≥1000/24 hours. This was not an independent predictor in other studies of heterogeneous populations of ARVC patients, 13, 32 nor was it predictive in females in this cohort in whom no clinical test predicted ICD discharges. Inappropriate discharges were present in 31% of males and 18% of females over the course of the study, with few other adverse effects.
From our previous studies, it is clear that the disease caused by this TMEM43 p.S358L mutation is different in men than in women, 6 a situation reflected in other inherited cardiomyopathies. 33, 34 In TMEM43 p.S358L ARVC, SCD occurred earlier in males, ICDs were inserted at a younger age (mean age 31years), and the survival benefit of the ICD was substantially larger.
An important message from this study is that ARVC TFC are unnecessary when risk status is defined by a mutation where segregation analysis has confirmed its disease-causing status. This situation allows the presymptomatic diagnosis of people at significant risk of SCD in the absence of clinically abnormal tests. Thus, many individuals with TMEM43 p.S358L were in the concealed phase of ARVC with a significant risk for SCD, yet undiagnosable using TFC. We previously presented the extensive variability of expression in mutation carriers, 6 reflecting the increasing recognition of clinical overlap in phenotype (eg, presenting with a dilated cardiomyopathy or ARVC) which can confound TFC. Individuals with classical ARVC are present in this population, 6 but their manifestations are not present in everyone.
Limitations
First, this is a cohort study from which cases and controls were identified. Although it is not a randomized control trial, it is the only study to our knowledge of ARVC therapy with a control group obtained using family members born at the same a priori 50% risk, matched for disease status, family, sex, and age. All available controls were used, and the analysis was confined to sibships in which ≥50% of siblings had a known ARVC disease status (to minimize the bias present in recognizing overt disease while missing concealed disease).
Assessing the clinical outcomes of treatment compared with historic matched controls is biased, but the outcomes for the control group for ICD PP males were the same as the control group for ICD SP males ( Figure I in the Data Supplement). Second, clinical data from the control group and from a minority of the ICD group were collected retrospectively. However, all available past records were collected from all Third, there is a selection bias present in the female ICD cohort because of implantation after individual preference, although others had an abnormal clinical test result. This makes optimal timing recommendations more difficult, but nonetheless the survival benefit is significant. Fourth, the definition of some affected control individuals (defined by SCD) in the absence of a mutation-positive test could be biased, but the clinical definition we used seems reasonable, and in 7 of 34 cases of SCD in controls where we were able to retrospectively obtain DNA from fixed autopsy tissue, all carried the TMEM43 p.S358L mutation. Fifth, we were not able to effectively determine drug therapy effects. In both the ICD and control cohorts, the drug type and dosage changed over time as the medications became available or were removed. It is unlikely that these affected the control cohort because only 12.8% ever had anti-arrhythmic drugs (half with Amiodarone). Sixth, we were not able to apply TFC to all individuals defined by TMEM43 p.S358L in this population because (1) many died with only an autopsy, (2) many had clinical testing comprising (at most) ECG, Holter, and echocardiography before death, (3) 5 were diagnosed by mutation and provided with an ICD in mainland Canada and the United States, but our access to their clinical test results is restricted from the time of inclusion in the study, and (4) the TFC are age/timebased, such that people prospectively change their status. Our primary endeavor was not to diagnose using TFC, rather to abort SCD and to assess the potential risk of heart failure and subsequent cardiac transplantation. Thus, in this population, the mutation is the most important piece of clinical information because those who have the mutation with minimal or no clinical signs have an overwhelming survival benefit with the ICD. Finally, the results pertain to the TMEM43 p.S358L mutation and thus may not be generalizable to ARVC families with different mutations who present with a less malignant phenotype.
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Advantages
The homogeneous nature of this cohort allows us to clearly determine ICD effectiveness and to define the natural history and clinical course of this disease. This results from the ability to identify familial controls, the availability of extensive medical data across the lifespan and across generations, and a high level of ascertainment. It is likely that this mutation is more common than is currently appreciated, 8, 9, 35, 36 in which case our data are of enormous importance to the clinical care of family members worldwide. However, in the TFC-defined ARVC literature, this remains an uncommon cause of ARVC and has a more malignant phenotype. We have the advantage of extensive family pedigrees and the ability to segregate the disease across many generations. In addition, we primarily based our diagnosis on a positive genetic test, not on TFC for ARVC, 4 ,5 an advantage which facilitated ascertainment before overt disease.
Conclusions
ICD therapy had a substantial and significant beneficial impact on survival in males whether the clinical indication was for PP or SP, and a less substantial yet significant benefit in females with the p.S358L mutation in TMEM43. SCD is often the first clinical event in mutation-positive individuals, and it is reasonable to consider sustained VT/VF ≥240 beats per minute terminated by an ICD an aborted death. ICD should be used in young postpubertal adult males based on genotype alone, whereas in females, implantation can be delayed until their late twenties/early thirties. 
SUPPLEMENTAL MATERIAL
